UNSPSC 51293610: Tiflucarbine

This classification denotes a serotonin agonist and antidepressant agent with the molecular formula C16H17FN2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M2108NUY0C, chemically known as 9-ethyl-4-fluoro-7,8,9,10-tetrahydro-1-methyl-6h-pyrido(4,3-b)thieno(3,2-e)indole but generally known as tiflucarbine, which bears US NIH Compound Identifier 65677. European Medicines Agency schedules Tiflucarbine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11043MIG.

UNSPSC 51293610 Tiflucarbine is a Commodity code, but the recent opportunities tagged under it do not involve tiflucarbine procurement; instead, they reflect state and local buying of naloxone, safe drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products through public health, health and human services, and cooperative purchasing channels. The mismatch between the code's nominal scope and the actual work being solicited suggests this code sees little relevant recent activity aligned with its stated commodity name.

The three recent opportunities span different issuing bodies and procurement stages. Seminole County, Florida posted IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually on a two-year contract with one-year renewal option, with quarterly deliveries to the Seminole County Community Health Building and a response deadline of July 26, 2023. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026, covering participating state and local government facilities including Oregon through three authorized wholesalers. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 as an exploratory market intelligence exercise regarding vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, with no binding timeline or award commitment. Geographic activity centers on Florida, Minnesota and Texas, with the MMCAP cooperative extending across multiple states including Oregon. The concentration of pharmaceutical and drug-response product procurement across these three distinct issuing bodies—a county health department, a multistate cooperative, and a state HHS agency—suggests moderate ongoing demand within state and local public health and human services operations, though the tiflucarbine code itself does not accurately reflect the commodities actually being purchased.